Clinical trials
Post-Acute COVID-19 Syndrome trials in Italy
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
29 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2020 | 1 |
| 2021 | 5 |
| 2022 | 11 |
| 2023 | 7 |
| 2024 | 2 |
| 2025 | 2 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 15 |
| Recruiting | 5 |
| Unknown status | 5 |
| Not yet recruiting | 2 |
| Active, not recruiting | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Federico II University | 2 |
| IRCCS Policlinico S. Donato | 2 |
| Istituti Clinici Scientifici Maugeri SpA | 2 |
| Azienda Ospedaliero, Universitaria Pisana | 1 |
| Azienda Socio Sanitaria Territoriale di Lecco | 1 |
| Azienda di Servizi alla Persona di Pavia | 1 |
| Catholic University of the Sacred Heart | 1 |
| Department of Neurorehabilitation, Hospital of Vipiteno-Sterzing (BZ) Italy | 1 |
| Douglas D. Fraser | 1 |
| Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Post-Acute COVID-19 Syndrome | 29 |
| COVID-19 | 14 |
| Fatigue | 3 |
| Dysbiosis | 2 |
| Abdominal Pain | 1 |
| Anxiety Disorders | 1 |
| Asthma | 1 |
| Bronchiectasis | 1 |
| Carcinoma, Non-Small-Cell Lung | 1 |
| Cognition Disorders | 1 |
Trials
Showing 1 to 25 of 29. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.